Order results by:
Issue | Title | |
Vol 7, No 4 (2014) | ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY | Abstract similar documents |
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky | ||
"... are not interested in price reduction at noncompetitive procedures. In the procurement of alternative drugs ..." | ||
Vol 18, No 1 (2025) | Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia | Abstract similar documents |
A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova | ||
"... of biosimilars on the market for public procurement of medicinal products based mAbs during the period 2022–2023 ..." | ||
Vol 17, No 3 (2024) | Assessment of the impact of procurement centralization on the drug provision for patients within the High-Cost Nosology Program in the Russian Federation | Abstract similar documents |
V. V. Omelyanovskiy, V. A. Ryagina, A. G. Kharitonova, K. I. Matrenin, A. A. Kingshott, O. V. Ashikhmina, M. V. Zhirov | ||
"... centralization on the weighted average price (WAP) per 1 unit of measurement (UM) of a drug, the procurement ..." | ||
Vol 18, No 2 (2025) | Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration | Abstract similar documents |
F. V. Gorkavenko, A. B. Goryachev, O. V. Ashikhmina, D. V. Fedyaev, N. V. Ignateva, E. A. Smolyarchuk, A. V. Kirchenko, D. D. Tkachenko, V. I. Brazhnikova | ||
"... , including assessment of the product range, price dynamics, demand and consumption, as well as index analysis ..." | ||
Vol 14, No 4 (2021) | Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy | Abstract similar documents |
N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev | ||
"... by regions for higher price, and centralized scenario with federal procurements and lower price for the drug ..." | ||
Vol 15, No 1 (2022) | Study of methods for state regulation of prices and costs of the health care system for medicines in the United Kingdom | Abstract similar documents |
A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
"... of prices and costs for the procurement of drugs was carried out based on information contained ..." | ||
Vol 12, No 2 (2019) | Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available | Abstract similar documents |
F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev | ||
"... trends in the general picture of drug prices and consumption. In the present study, we analyze ..." | ||
Vol 7, No 2 (2014) | ANALYSIS OF DRUG PRODUCTS ASSORTMENT ACQUIRABLE BY HEALTHCARE ORGANIZATIONS FOR MEDICAL TREATMENT IN HOSPITAL SETTINGS WAS CONDUCTED | Abstract similar documents |
M. G. Malaev | ||
Vol 14, No 2 (2021) | Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting | Abstract similar documents |
E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov | ||
"... based on the maximum registered prices, recommended doses and treatment regimens. The normative legal ..." | ||
Vol 12, No 4 (2019) | Clinical and economic analysis of drug costs in a general hospital in 2014-2018 | Abstract similar documents |
A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova | ||
"... results prompted a reassessment of the drug procurement policy and readjustment of the financial resources ..." | ||
Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
"... на уровне субъекта РФ по мере истечения сроков патентной защиты лекарственных препаратов (ЛП ..." | ||
Vol 18, No 2 (2025) | Data analysis of medicines aimed at health technology assessment within the activities of the “Circle of Kindness” Foundation from 2021 to 2024 | Abstract similar documents |
V. V. Omelyanovskiy, A. A. Kingshott, T. S. Teptsova, P. A. Mukhortova, A. G. Kharitonova, S. I. Zinadinov, L. O. Krekhtunova, N. A. Aldushchenko, A. А. Kozak, V. A. Ryagina | ||
"... in the procurement lists of the “Circle of Kindness” Foundation is provided by health technology assessment conducted ..." | ||
Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
"... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..." | ||
Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
"... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..." | ||
Vol 10, No 4 (2017) | IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET | Abstract similar documents |
V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva | ||
"... the therapeutic value of the drug into its consumer price. The drug pricing system existing in the Russian ..." | ||
Vol 10, No 3 (2017) | Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis | Abstract similar documents |
E. V. Biryukova, V. I. Ignat’eva | ||
"... ) or the ready-made mixtures (biphasic 25 or 50 lispro). The weighted average price of 1 IU insulin (according ..." | ||
Vol 11, No 4 (2018) | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer | Abstract similar documents |
N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov | ||
"... direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment ..." | ||
Vol 13, No 2 (2020) | Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union | Abstract similar documents |
A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
"... Aim. To analyze the methods of the state regulation of prices for the manufacturers ..." | ||
Vol 7, No 4 (2014) | ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS | Abstract similar documents |
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva | ||
"... study goal is to prepare a road map for development of price regulation system and system of drug ..." | ||
Vol 17, No 1 (2024) | Analysis of the availability of bronchodilators and anti-inflammatory drugs for patients with chronic obstructive pulmonary disease | Abstract PDF (Eng) similar documents |
E. A. Orlova, V. I. Petrov, I. P. Dorfman, O. V. Shatalova, M. A. Orlov | ||
"... in the Russian Federation. Objective: to assess drug prices, affordability, and availability for COPD patients ..." | ||
Vol 17, No 4 (2024) | The joint use of ABC/VEN analysis and the Beers criteria for optimizing expenditure of funds and rational prescribing of medications to elderly patients | Abstract similar documents |
O. A. Makhmudova, G. F. Avkhadieva, O. G. Bagdanova, V. N. Khaziakhmetova | ||
"... ) in A, B, C groups. In 2019, 13.7% of the budget was spent on the procurements of drugs of N category ..." | ||
Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
M. B. Kubaeva, Y. Sh. Guchshina | ||
"... -sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy. ..." | ||
Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
E. A. Pyadushkina, M. Yu. Frolov | ||
"... . The costs in model are calculated on the basis of registered prices on drugs from the List of vital ..." | ||
Vol 10, No 2 (2017) | PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA | Abstract similar documents |
M. Yu. Frolov, O. V. Shatalova | ||
"... procurement. If introduced this program can save the Federal budget up to 232 785 963 rubles. Conclusion ..." | ||
Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
"... to December 2015. The data of state statistical supervision, registered limit transfer drug prices from ..." | ||
Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
"... as indicated, taking into consideration the new registered price. Material and methods. A clinical-economic ..." | ||
Vol 14, No 3 (2021) | Pharmacoeconomic features of drug provision to the rheumatology department of the republican clinical hospital | Abstract similar documents |
L. N. Sheikhmambetova, E. A. Egorova, K. N. Onishchenko, E. I. Konyaeva | ||
"... expenditure was carried out using ABC/VEN analysis. Results. The total expenditure on the procurement ..." | ||
Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
N. A. Avxentyev, Yu. V. Makarova | ||
"... state procurement of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in 2021, we ..." | ||
Vol 12, No 3 (2019) | Clinical and economic analysis as an instrument for harmonizing import substitution in the preferential segment of medicinal support | Abstract similar documents |
E. V. Eliseeva , E. S. Maneeva , R. K. Goncharova , A. V. Kropotov | ||
"... analogues) and subjective (irrational approaches to the procurement of medicines due to the lack ..." | ||
Vol 18, No 1 (2025) | The sale of medicines used for diabetes mellitus treatment in retail segment of Russian pharmaceutical market | Abstract similar documents |
I. K. Petrukhina, A. M. Lazarev, T. K. Ryazanova, P. A. Lebedev, E. P. Gladunova, G. T. Glembotskaya | ||
"... period, the weighted average price (WAP) per 1 package of a drug for DM treatment increased from 472 ..." | ||
Vol 17, No 4 (2024) | Pharmacoeconomic study of active psoriatic arthritis treatment | Abstract similar documents |
A. V. Rudakova, Т. V. Korotaeva | ||
"... retail prices, inclusive of value-added tax. In case of availability of biosimilars/generics ..." | ||
Vol 15, No 3 (2022) | Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study | Abstract similar documents |
V. V. Strizheletsky, Yu. М. Gomon, Е. А. Spichakova, А. S. Kolbin, А. А. Kalyapin, S. А. Makarov, А. B. Lomiya, F. М. Sultanova | ||
"... . Material and methods. From IQVIA database, the information was selected on retail sales and procurement ..." | ||
Vol 14, No 2 (2021) | Analysis of the availability and affordability of pharmaceuticals for children in need of palliative care | Abstract similar documents |
D. M. Medvedeva, I. A. Narkevich, O. D. Nemyatykh | ||
"... of palliative care. Materials and methods. The price, affordability and physical availability ..." | ||
Vol 15, No 2 (2022) | The current state of the veterinary drugs market in the Tyumen Region | Abstract similar documents |
V. V. Byshenko, О. I. Knysh, L. N. Zadirachenko, А. О. Egorova, Yu. S. Rodina | ||
"... clinics in the Tyumen Region (33); price lists of veterinary pharmaceutical organizations; questionnaires ..." | ||
Vol 13, No 4 (2020) | Concept of value-based healthcare | Abstract similar documents |
N. Z. Musina, V. V. Omelyanovskiy, R. V. Gostischev, O. A. Sukhorukikh, V. K. Fedyaeva, N. N. Sisigina, D. G. Shchurov | ||
"... processes including procurement of drugs and medical devices, their pricing, and reimbursement. ..." | ||
Vol 10, No 2 (2017) | THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS | Abstract similar documents |
V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko | ||
"... as a major criterion in negotiations on medicine prices. The existing tools for assessing the therapeutic ..." | ||
Vol 16, No 1 (2023) | Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 | Abstract similar documents |
D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin | ||
"... Information System for Procurement for the period from July to December 2022 inclusive. The budget impact ..." | ||
Vol 11, No 2 (2018) | Introduction of medical products into healthcare practice and costs reimbursement: European experience | Abstract similar documents |
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii | ||
Vol 17, No 2 (2024) | Mathematical modeling and analysis of export trends for certain pharmaceutical groups | Abstract similar documents |
А. R. Shaikhislamova, N. А. Gasratova | ||
"... on various economic indicators, such as gross domestic product, the volume of government procurement ..." | ||
Vol 9, No 3 (2016) | DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY | Abstract similar documents |
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov | ||
"... (procurement of essential drugs (EDPP) and of regional benefits (RBP)). Materials and Methods. We collected ..." | ||
Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
"... regimens were calculated from the registered data on the maximum selling prices of VED drugs or from ..." | ||
Vol 8, No 3 (2015) | COMPARATIVE PHARMACOECONOMIC STUDY OF VITAMIN-MINERAL COMPLEXES FOR REHABILITATION DURING THE PERIOD OF INCREASED NEEDS FOR MICRONUTRIENTS | Abstract similar documents |
A. Yu. Belinskaya, I. Yu. Torshin, T. R. Grishina, O. A. Gromova | ||
"... CMC both in quality and price. Results: Based on the assessment of pharmacological quality and price ..." | ||
Vol 17, No 4 (2024) | Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system | Abstract similar documents |
A. V. Rudakova, I. Z. Gaydukova | ||
"... to the registered maximum retail prices, inclusive of value-added tax. In case of availability of biosimilars ..." | ||
Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
"... of orphan drugs and to carry out state regulation of prices, to ensure increase of regional funding ..." | ||
Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
A. G. Tolkushin, N. L. Pogudina | ||
"... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..." | ||
Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
E. A. Pyadushkina | ||
"... analysis, published reports on inflammatory bowel disease (IBD) treatment, the highest quoted prices ..." | ||
Vol 7, No 4 (2014) | IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? | Abstract similar documents |
V. V. Omelyanovskiy | ||
"... , internal and external price regulation can be distinguished. External referencing system has been used ..." | ||
Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract similar documents |
V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
"... of antimicrobial treatment calculated with a reference to the price and the percentage of total AMDs administered ..." | ||
Vol 14, No 4 (2021) | Features of intellectual property protection mechanisms on the example of orphan drugs circulation | Abstract similar documents |
D. S. Yurochkin, К. V. Nasonova, Z. М. Golant, I. А. Narkevich, V. P. Trukhin | ||
"... by the regulatory authority, it is necessary to establish reasonable marginal prices, to form a sufficient set ..." | ||
Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
S. К. Zyryanov, I. N. Dyakov | ||
"... on the registered prices according to the state register of maximum selling prices. Results. The use ..." | ||
1 - 50 of 276 Items | 1 2 3 4 5 6 > >> |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)